CyBeR Association in Relapsed/Refractory DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
- Status
- COMPLETED
- Phase
- PHASE2
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
- Status
- COMPLETED
- Phase
- PHASE1
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
- Status
- RECRUITING
- Phase
- PHASE3
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- Status
- RECRUITING
- Phase
- PHASE3
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
- Status
- UNKNOWN
- Phase
- PHASE2
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1